Hepatitis C Articles



Guidelines for the Management of Hepatitis C Virus Infection

Following is the "Brief Summary" of the medical position statement on the management of hepatitis C from the American Gastroenterological Association (AGA). This is the current release of the guidelines from the AGA, published in Gastroenterology (January 2006). A link to the Complete Summary of the Guidelines is also provided.

According to the guideline developer, the Clinical Practice Committee meets three times a year to review all American Gastroenterological Association Institute (AGAI) guidelines. This review includes new literature searches of electronic databases followed by expert committee review of new evidence that has emerged since the original publication date.

It is important to stress that these recommendations should not be construed as a standard of care. The AGA stresses that the final decision regarding the care of the patient should be made by the physician with a focus on all aspects of the patient's current medical situation.

This document presents the official recommendations of the American Gastroenterological Association (AGA) on "Management of Hepatitis C."

Brief Summary Content

Recommendations
Evidence Supporting the Recommendations
Identifying Information and Availability
Disclaimer
Go to the Complete Summary

 

FDA-approved Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved Combination Therapies for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin